GeneSpector Announces Collaborative Agreement with Thermo Fisher Scientific EMEA Ltd.25/08/24
GeneSpector today announced a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.
This collaboration will enable GeneSpector and Thermo Fisher to collaboratively develop and potentially commercialize a range of diagnostic solutions. These include a new severity biomarker for respiratory infections and a prognostic kit for the detection of pregnancy-related complications. The collaboration will leverage Thermo Fisher's expertise to advance new technologies and develop novel prognostic and diagnostic biomarkers being created at GeneSpector.
Michal Pohludka, founder and CEO of GeneSpector, commented: "We are honored to be working closely with a world leader like Thermo Fisher to accelerate the development of our exciting new products. Our ultimate goal is to introduce new biomarkers to the market that will aid physicians in making informed treatment decisions and improve patient outcomes. This collaboration with Thermo Fisher underscores our capability and ambition to build a clinical diagnostics company with a global reach and impact, reinforcing both the technical and commercial strengths of our laboratory testing business."
Peter Jacobs, Director of EMEA Business Development, Genetic Sciences Division at Thermo Fisher Scientific, said: “We are excited about the opportunity to collaborate with GeneSpector on several of their new clinical diagnostic products. We are confident that together, we will achieve rapid progress and deliver innovative technologies and assays to the global clinical marketplace.”
About Thermo Fisher Scientific
Thermo Fisher Scientific EMEA Ltd is part of Thermo Fisher Scientific Inc. (NYSE: TMO) which is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
About GeneSpector
GeneSpector is an incubator and accelerator driving innovative ideas in clinical diagnostics from discovery to proof-of-concept. The proprietary approaches are commercialized through either licensing to industry leaders or the formation of focused spin-off ventures with dedicated research and business development teams.
As a spin-off of Charles University, GeneSpector has a direct collaboration with its researchers. A Co-Founder SPADIA LAB, a.s. is a crucial element of GeneSpector success thanks to its involvement in commercial laboratory diagnostics, 1/ Provides implementation and testing of developed solutions and 2/ Provides insight and information regarding real-life market needs and bottlenecks that are directly addressed and resolved by our products.
GeneSpector Contact:
Michal Pohludka, CEO
+420 602 659 211